Article Sidebar

PDF
Date Published: 05/07/2023
Abstract Views: 640
Views PDF: 259
DOI: https://doi.org/10.51298/vmj.v527i2.5889
Issue
Vol. 527 No. 2 (2023)
Section
Các bài báo
How to Cite
Phùng , L. T., Ong , T. D., Đỗ, T. M., Đỗ, Q. T., & Nguyễn, T. V. (2023). COST-EFFECTIVENESS OF AFATINIB IN TREATMENT FOR NON-SMALL CELL LUNG CANCER WITH EGFR MUTATION IN VIETNAM. Vietnam Medical Journal, 527(2). https://doi.org/10.51298/vmj.v527i2.5889

COST-EFFECTIVENESS OF AFATINIB IN TREATMENT FOR NON-SMALL CELL LUNG CANCER WITH EGFR MUTATION IN VIETNAM

Lâm Tới Phùng 1,, Thế Duệ Ong 1, Trà My Đỗ1, Quỳnh Trang Đỗ1, Tuấn Việt Nguyễn1
1 Institute of Health Strategy & Policy - Ministry of Health

Main Article Content

Abstract

Objective: To evaluate the cost-effectiveness of Afatinib compared to Gefitinib and Erlotinib in the treatment of non-small cell lung cancer with EGFR mutations in Vietnam. Methods: A model-based cost-effectiveness analysis was conducted which employed the payer's perspective. The partition survival modeling (PSM) was used to simulate the survival time of the non-progressive disease and the overall survival time of the study patient population, with a time horizon of 10 years and a cycle length of 1 month. Treatment cost parameters and adverse event management are collected based on clinical expert consultation. Parameters of clinical efficacy and quality of life are collected from published sources. Results: The treatment regimen with Afatinib had a higher total cost than Gefitinib and Erlotinib, and the number of life years gained and QALY gained was also higher than that of Gefitinib and Erlotinib. The ICER index is VND 178,694,204 and VND 190,963,102 for each additional QALY. Conclusion: The treatment of non-small cell lung cancer with EGFR mutation in Vietnam with Afatinib is cost-effective when compared to Gefitinib and Erlotinib.

Article Details

Keywords

Non-small cell lung cancer, cost-effectiveness, afatinib, gefitinib, erlotinib

References

1. American Cancer Society. Cancer Facts & Figures 2022. 2022; Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/2022-cancer-facts-and-figures.pdf.
2. Paz-Ares, L., et al., Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol, 2017. 28(2): p. 270-277.
3. Yang, J.C., et al., Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol, 2015. 16(7): p. 830-8.
4. Park, K., et al., Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol, 2016. 17(5): p. 577-89.
5. Gu, X., et al., Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Lung Cancer, 2019. 127: p. 84-89.
6. Kim, Y.J., et al., Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada. Pharmacoeconomics, 2021. 39(5): p. 537-548.